- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.05. | Zeno appoints Cendrine Seror as Head of Health, Europe | ||
| 13.05. | AbbVie Appoints Kelly Sanderson Schrems as UK VP and General Manager | ||
| 13.05. | Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases | ||
| 12.05. | Novartis breaks ground on US radioligand therapy site | ||
| 12.05. | OVID Health has appointed Davide Scalenghe as Head of Global Strategy & Partnerships | ||
| 11.05. | LEO Pharma to acquire Replay gene therapy platform | ||
| 11.05. | Cue Biopharma appoints Shao-Lee Lin as CEO, President and Director | ||
| 08.05. | Legend Biotech appoints new group of scientific advisors | ||
| 07.05. | Lilly commits additional $4.5bn for US manufacturing sites | ||
| 07.05. | Langland appoints Victoria Kent as Managing Partner, Medical Strategy & Education | ||
| 06.05. | FDA gives Rare Paediatric Disease designation to Satellite Bio for urea cycle disorders | ||
| 06.05. | GC Therapeutics appoints Stefan Irion as Chief Scientific Officer | ||
| 05.05. | adelo acquires Dot I/O Health, with Nigel Breakwell becoming Managing Partner | ||
| 05.05. | Innovative Trials appoints Anita Owen as first COO | ||
| 01.05. | UCB presentation highlights impacts of epilepsy on daily life | ||
| 01.05. | Inventiva appoints Axel-Sven Malkomes as Chief Financial Officer | ||
| 30.04. | Biogen agrees $850m felzartamab rights deal with TJ Biopharma | ||
| 30.04. | myTomorrows partners with Rare Disease Research to boost rare disease referrals | ||
| 29.04. | Helus Pharma appoints Ken Kramer as Senior VP, Medical Affairs | ||
| 29.04. | Why the field is critical tonext-generation marketing | ||
| 29.04. | Sanofi's Tzield gets expanded FDA approval for early-stage type 1 diabetes | ||
| 28.04. | AstraZeneca reports positive phase 3 data for tozorakimab in COPD | ||
| 28.04. | AI-powered launches on a limited budget: a playbook for emerging biopharma | ||
| 27.04. | Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn | ||
| 27.04. | MHRA authorises Biogen's higher-dose Spinraza for SMA treatment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.